文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

非ST段抬高急性冠脉综合征中P2Y12受体阻滞剂下游或上游给药:随机对照试验研究方案

Downstream or upstream administration of P2Y12 receptor blockers in non-ST elevated acute coronary syndromes: study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2020-11-24

DUBIUS研究为4期多中心双随机试验,纳入2520例NSTE-ACS患者,比较替格瑞洛预处理与下游给药策略,并将下游PCI组进一步随机分为普拉格雷或替格瑞洛。主要假设为下游策略优于上游策略,且下游替格瑞洛非劣于下游普拉格雷,复合终点包括血管性死亡、非致死性心梗或非致死性卒中及BARC 3、4、5型出血。

要点

  • NSTE-ACS患者替格瑞洛预处理与下游P2Y12抑制剂给药策略的头对头比较。
  • 下游PCI组进一步随机比较普拉格雷与替格瑞洛的疗效与安全性。
  • 复合终点含血管性死亡、非致死性心梗/卒中及BARC 3、4、5型出血。

核心结论

  • DUBIUS研究将提供替格瑞洛预处理与不预处理策略获益风险对比的重要证据。
  • 研究还将评估下游替格瑞洛与下游普拉格雷相比的临床影响。

研究设计与样本

  • DUBIUS为4期、多中心、平行组、双随机研究,在NSTE-ACS患者中开展。
  • 共2520例患者随机分配至替格瑞洛预处理组或不预处理组。
  • 下游组中PCI亚组进一步随机接受普拉格雷或替格瑞洛。

关键数值与推荐

  • 主要假设一:下游策略优于上游策略,以复合疗效与安全性终点发生率衡量。
  • 主要假设二:下游替格瑞洛非劣于下游普拉格雷,以相同复合终点衡量。
  • 复合终点包括血管性死亡、非致死性心梗或非致死性卒中,以及BARC 3、4、5型出血。
  • 预处理策略仅包括替格瑞洛,下游策略包括普拉格雷或替格瑞洛。

临床怎么用

  • 研究结果可为NSTE-ACS患者P2Y12抑制剂给药时机选择提供随机对照证据。
  • 研究结果可指导下游给药时替格瑞洛与普拉格雷的选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The optimal timing to administer a P2Y12 inhibitor in patients presenting with a non-ST elevation acute coronary syndrome remains a topic of debate. Pretreatment with ticagrelor before coronary anatomy is known as a widely adopted strategy. However, there is poor evidence on how this compares with administration of a P2Y12 inhibitor after defining coronary anatomy (i.e., downstream administration). Moreover, there are limited head-to-head comparisons of the two P2Y12 inhibitors-ticagrelor and prasugrel-currently recommended by the guidelines. STUDY DESIGN: DUBIUS is a phase 4, multicenter, parallel-group, double randomized study conducted in NSTE-ACS patients designed to compare a pretreatment strategy (including only ticagrelor) versus a downstream strategy (including prasugrel or ticagrelor) and to compare downstream prasugrel with downstream ticagrelor. A total of 2520 patients will be randomly assigned to pretreatment with ticagrelor or to no pretreatment. The PCI group of the downstream arm will be further randomized to receive prasugrel or ticagrelor. The two primary hypotheses are that the downstream strategy is superior to the upstream strategy and that downstream ticagrelor is non-inferior to downstream prasugrel, both measured by the incidence of a composite efficacy and safety endpoint of death from vascular causes, non-fatal MI, or non-fatal stroke, and Bleeding Academic Research Consortium (BARC) type 3, 4, and 5 bleedings. CONCLUSIONS: The DUBIUS study will provide important evidence related to the benefits and risks of pretreatment with ticagrelor compared with a strategy of no pretreatment. Moreover, the clinical impact of using downstream ticagrelor compared with downstream prasugrel will be assessed. TRIAL REGISTRATION: ClinicalTrials.gov NCT02618837 . Registered on 1 December 2015.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Tarantini G, Mojoli M, Varbella F, et al. Downstream or upstream administration of P2Y12 receptor blockers in non-ST elevated acute coronary syndromes: study protocol for a randomized controlled trial. Trials. 2020. PMID: 33234137. doi:10.1186/s13063-020-04859-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。